Tiantian Sun

Title: Tiantian Sun: Innovator in Biopharmaceuticals

Introduction

Tiantian Sun is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapies for cancer treatment. With a total of 4 patents, his work focuses on enhancing the immune response against various diseases.

Latest Patents

One of his latest patents is titled "Anti-B7S1 Polypeptides and Their Use." This invention relates to anti-B7S1 (B7-H4) polypeptides, including antibodies and their immunoreactive fragments. It also involves chimeric antigen receptors (CAR) that bind to the B7S1 (B7-H4) molecule, specifically for cancer treatment. The invention emphasizes humanized anti-B7S1 antibodies and their fragments, which can boost the immune system's activation against cancerous cells. Another notable patent is "Anti-IL-25 Antibodies and Use Thereof," which provides anti-IL-25 antibodies directed against human IL-25, along with the nucleic acids encoding these antibodies and their pharmaceutical compositions.

Career Highlights

Tiantian Sun has worked with notable companies in the biopharmaceutical sector, including Suzhou Kanova Biopharmaceutical Co., Ltd. and Beijing Kanova Biopharmaceutical Co., Ltd. His expertise in the field has led to advancements in therapeutic approaches for treating various diseases.

Collaborations

Throughout his career, Tiantian has collaborated with esteemed colleagues, including Li Hui Guo and Chen Dong. These partnerships have contributed to the development of innovative solutions in biopharmaceutical research.

Conclusion

Tiantian Sun's contributions to biopharmaceuticals, particularly in cancer treatment, highlight his role as a leading inventor in the field. His innovative patents and collaborations continue to pave the way for advancements in medical therapies.